KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Common Equity (2016 - 2025)

Abbott Laboratories' Common Equity history spans 17 years, with the latest figure at $52.8 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 10.17% year-over-year to $52.8 billion; the TTM value through Dec 2025 reached $52.8 billion, up 10.17%, while the annual FY2025 figure was $52.8 billion, 10.17% up from the prior year.
  • Common Equity for Q4 2025 was $52.8 billion at Abbott Laboratories, up from $51.3 billion in the prior quarter.
  • Across five years, Common Equity topped out at $52.8 billion in Q4 2025 and bottomed at -$15.7 billion in Q2 2023.
  • The 5-year median for Common Equity is $222.5 million (2021), against an average of $10.5 billion.
  • The largest annual shift saw Common Equity tumbled 13098.08% in 2022 before it surged 116731.71% in 2024.
  • A 5-year view of Common Equity shows it stood at $31.5 billion in 2021, then crashed by 148.3% to -$15.2 billion in 2022, then skyrocketed by 100.27% to $41.0 million in 2023, then soared by 116731.71% to $47.9 billion in 2024, then grew by 10.17% to $52.8 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Common Equity are $52.8 billion (Q4 2025), $51.3 billion (Q3 2025), and $264.0 million (Q2 2025).